Preimplantation genetic testing for aneuploidy (PGT-A) is a technique utilized during in vitro fertilization (IVF) to screen embryos for chromosomal abnormalities before implantation. Patients considering PGT-A should take several factors into account:

1. Age of the woman: Advanced maternal age is associated with an increased risk of chromosomally abnormal embryos. PGT-A can help identify genetically normal embryos for transfer and increase the chances of a successful pregnancy.

2. Previous miscarriages or failed IVF cycles: Patients with a history of recurrent miscarriages or unsuccessful IVF cycles may benefit from PGT-A to select embryos with the highest chance of implantation and full-term development.

3. Genetic conditions: Couples with known genetic disorders or chromosomal abnormalities may opt for PGT-A to reduce the risk of passing on these conditions to their offspring by selecting embryos without the specific genetic abnormalities.

4. Quality of embryos: PGT-A can help identify embryos with the correct number of chromosomes, which are more likely to implant successfully and result in a healthy pregnancy.

5. Emotional and financial considerations: Patients should also consider the emotional toll of potential pregnancy loss or raising a child with genetic abnormalities. Additionally, the cost of PGT-A should be factored into the decision-making process.

PGT-A enhances IVF success by improving the selection of embryos for transfer. By identifying chromosomally normal embryos, PGT-A decreases the likelihood of